Company intelligence / Profile preview

CanCertain

Manchester, England, United Kingdomcancertain.com ↗

Ownership: Private
Development stage: Other

Overview

CanCertain offers a clinically validated, rapid turnaround diagnostic service that uses advanced 3D cell culture techniques on patient-derived tumor samples to recommend the most effective cancer treatment. The test has demonstrated an accuracy rate of approximately 90% in identifying optimal therapies and aims to improve quality of life and survival by reducing unnecessary rounds of ineffective drugs[1].

Therapeutic areas: Oncology
Modalities: 3D cell culture-based assay
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on CanCertain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanCertain.

Explore the full profile